News

AstraZeneca Strikes Exclusive Licensing Deal with Eccogene for ECC5004

1 2 3 4 5

4.6

Andrew R. Michaud

• November 09, 2023

AstraZeneca has announced an exclusive agreement with Eccogene to license the ECC5004 product, which holds promise in treating conditions like type-2 diabetes and obesity.

Key Terms of the Agreement

According to AstraZeneca, the deal includes an initial payment of $185 million to Eccogene for ECC5004. Additionally, AstraZeneca has committed to paying up to $1.825 billion in the future as part of clinical, regulatory, and commercial milestones. The agreement also outlines tiered royalties for AstraZeneca based on product net sales.

Global Rights for AstraZeneca

Under the agreement, AstraZeneca gains exclusive global rights for the development and commercialization of Eccogene's ECC5004 small molecule GLP-1RA, except in China. In China, Eccogene will have the right to co-develop and co-commercialize the drug.

Promising Product for Cardiometabolic Conditions

ECC5004 is an oral, once-daily glucagon-like peptide 1 receptor agonist (GLP-1RA) designed to address obesity, type-2 diabetes, and other cardiometabolic conditions. Preliminary results from a Phase 1 clinical trial have shown strong efficacy and safety profiles for ECC5004. Notably, the drug has displayed good tolerability and has demonstrated positive effects on glucose and body weight reduction as compared to a placebo.